Launching a Phase 3 Pivotal Trial in a Pandemic with the Medidata Rave Clinical Cloud
Downloadable Case Study
Launching a Phase 3 Pivotal Trial in a Pandemic with the Medidata Rave Clinical Cloud
TissueTech was set to launch a Phase 3 pivotal trial for the treatment of severe diabetic foot ulcers in March 2020—just as governments began lockdowns to combat the spread of COVID-19.
Download this case study to see how TissueTech adapted to pandemic restrictions with the Medidata Rave Clinical Cloud by:
- Protecting patient safety with remote visits
- Increasing trial efficiency and effectiveness with Rave TSDV (Total Source Data Verification)
- Reducing the burden on sites by using a cloud-based platform with a single log-in
- Enabling study monitors to remotely review source documents, avoiding site visits
About TissueTech
Founded in 1997, TissueTech is a pioneer in the development and clinical application of human birth tissue-based products for regenerative medicine. TissueTech’s products have been used in more than 500,000 human clinical applications and studied and documented in more than 360 peer-reviewed publications.